IdentifySensors

IdentifySensors is pioneering a novel digital diagnostics platform centered on its Check4™ system, which utilizes solid-state, graphene-based biosensors for direct molecular recognition. The platform is initially focused on detecting clinically actionable cancer mutations (e.g., EGFR, KRAS) with the goal of enabling rapid therapy selection, resistance monitoring, and minimal residual disease assessment. As a platform technology, it is designed to expand into multiplex testing for infectious diseases and other biomarkers, operating on a SaaS business model. The company is in the development stage, having initiated FDA submissions in Q2 2025, and is positioning itself to address the need for affordable, decentralized, and rapid molecular testing.

Check4™ digital diagnostic platform using printed electronic semiconductor (graphene-based) biosensors for direct, label-free, amplification-free molecular detection. The system includes a reusable Bluetooth reader, disposable cartridges, and cloud-based analytics.

IdentifySensors competes in the molecular diagnostics space against large central lab providers (e.g., Quest, Labcorp), companies offering lab-based liquid biopsy and sequencing (e.g., Guardant Health, Foundation Medicine), and established point-of-care molecular system vendors (e.g., Cepheid/BioFire). Its differentiation hinges on achieving a unique combination of high sensitivity, speed, low cost, and true point-of-care usability without complex workflows.